Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments-Reference-Cited by-同舟云学术

Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

Published:2015-02-02 Issue:4 Volume:14 Page:952-963
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Loganzo Frank,Tan Xingzhi,Sung Matthew,Jin Guixian,Myers Jeremy S.,Melamud Eugene,Wang Fang,Diesl Veronica,Follettie Maximillian T.,Musto Sylvia,Lam My-Hanh,Hu William,Charati Manoj B.,Khandke Kiran,Kim Kenny Sung Kyoo,Cinque Mike,Lucas Judy,Graziani Edmund,Maderna Andreas,O'Donnell Christopher J.,Arndt Kim T.,Gerber Hans-Peter

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads;European Journal of Medicinal Chemistry;2024-10

2. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04

3. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer;Journal of Experimental & Clinical Cancer Research;2024-08-21

4. History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region;Frontiers in Pharmacology;2024-08-06

5. Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs;World Journal of Oncology;2024-08